Analyst consensus rating
Aytu BioPharma Analyst Rating: none
Direct answer
Aytu BioPharma's consensus rating is none.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $9.67.
Forecast evidence checked November 14, 2026.
Get free Aytu BioPharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.78
- Average price target
- $9.67
- High price target
- $15.00
- Low price target
- $7.00
- Low target gap
- +293.3%
- Target upside
- +443.1%
- High target gap
- +742.7%
- Target range width
- 449.4%
- Consensus rating
- none
- Analysts
- 3
- Evidence date
- November 14, 2026
- Valid through
- November 21, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Aytu BioPharma?
Aytu BioPharma has a verified none consensus. The same dataset has an average price target of $9.67.
How far are Aytu BioPharma's low and high targets from the recorded price?
The low target implies +293.3%, while the high target implies +742.7%.
How many analysts are included in Aytu BioPharma's consensus?
The verified consensus includes 3 analysts.
How is Aytu BioPharma's target upside or downside calculated?
The average target of $9.67 is divided by the recorded price of $1.78, then one is subtracted to produce +443.1%. This does not guarantee a future return.
When was Aytu BioPharma's analyst forecast verified?
The data was verified on 2026-11-14. The dataset is valid through 2026-11-21.